These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27052853)

  • 1. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
    Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
    Jönsson S; Olsson B; Söderberg J; Wadenvik H
    Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.
    Uyanik MS; Pamuk GE; Maden M; Merev E; Cevik G; Uyanik V; Umit EG; Demir AM; Akker M
    Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26594025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy.
    Al-Ghazaly J; Al-Dubai W; Noaman Y; Abdullah M; Al-Gharasi L; Rosti G
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):e144-e153. PubMed ID: 31983635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
    Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
    Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
    Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
    Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
    Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
    Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
    de Almeida MH; Pagnano KB; Vigorito AC; Lorand-Metze I; de Souza CA
    Acta Haematol; 2013; 130(1):16-22. PubMed ID: 23363706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.
    Geissler J; Sharf G; Bombaci F; Daban M; De Jong J; Gavin T; Pelouchova J; Dziwinski E; Hasford J; Hoffmann VS
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1167-1176. PubMed ID: 28289895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study.
    Wang Y; Zhang P; Han Y; Nelson RS; McLeod HL; Tao K; Yuan Y; Zhang M; Xiang H; Zhou H
    Chemotherapy; 2019; 64(4):197-204. PubMed ID: 31955170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
    Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A
    Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in Adherence Measures to Imatinib Therapy.
    Yanamandra U; Malhotra P; Sahu KK; Sushma Y; Saini N; Chauhan P; Gill J; Rikhi D; Khadwal A; Prakash G; Lad D; Suri V; Kumari S; Varma N; Varma S
    J Glob Oncol; 2018 Sep; 4():1-10. PubMed ID: 30241224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
    Noens L; van Lierde MA; De Bock R; Verhoef G; Zachée P; Berneman Z; Martiat P; Mineur P; Van Eygen K; MacDonald K; De Geest S; Albrecht T; Abraham I
    Blood; 2009 May; 113(22):5401-11. PubMed ID: 19349618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.